Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS OUT
Omni Health, Inc. Announces Roll Out of Anti-Aging Product Line
MIAMI, FL -- (Marketwired) -- 06/13/17 -- Omni Health, Inc., (OTC PINK: OMHE), a vertically integrated healthcare company with focus on pharmaceutical, anti-aging products, and cannabis biotech engineering, announced today the roll out of Celeb Cream, anti-aging product line. Dr. Lawrence Samuels, a member of the Scientific Advisory Board of OMHE, was the scientific engineer of the Celeb Cream original products. Celeb Cream is an all-in-one anti-aging complex with the most effective peptides clinically proven to reduce appearance of wrinkles. For more information on Celeb Cream visit www.celebcream.com.
Celeb Cream, Inc., expects to bring more than $2M in revenue to OMHE over the course of the next year, increasing OMHE projections for this fiscal year to more than $10M in revenue. Andrey Soloviev, OMHE Chief Executive Officer, stated, "When we acquired Malecon Pharmacy approximately one year ago, it was our intent then to bring Celeb Cream into the business. We just needed to wait for the right time to make it happen." The roll-up of Celeb Cream into OMHE was without any shareholder dilution.
Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely respected leader in his medical field, has been developing anti-aging, skin care, and hair care products since 1966. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.
"This Celeb Cream addition will allow us to fast track Omni Health's entry into the anti-aging and specialty skincare industries, a highly profitable marketplace that we have targeted as one of the key growth areas," said Omni Health CEO Andrey Soloviev.
For more information about Omni Health, go to www.OmniHealth.md
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
Contact:
Andrey Soloviev
Chief Executive Officer
ceo@OmniHealth.md
Source: Omni Health Inc.?
942k shares traded today in a VERY tight range... hoping to see it pop soon !
The promo has ended, "Promotion Launch Begins May 26 to June 9
https://marathonhcc06.clickfunnels.com/outdoorlife
GREAT DD FLa is a real weird requirements and the laws are always changing little by little. Lets hope for a good push next week past the .045's
bensonfoldsfive,
check out CRYO... it was trading in the mid .20s now trading in the mid .40s and just broke .50... GREAT company w/ a low float in the stem cell business..
just sit back and watch...
Agreed.. This stock will start moving next week and will be much higher later in the year.. as i mentioned before, it will be FUN watching shorts cover.
GREAT day ... broke the .49s and looked like all BUYING !!
Time and Sales for American Cryostem Corp (CRYO) Jun 09, 2017
Symbol:
CRYO
GO
Time Price Volume Market
15:54:03 0.50 410 OTO
15:51:50 0.50 500 OTO
15:50:19 0.49 7700 OTO
15:47:40 0.49 800 OTO
15:47:40 0.49 1200 OTO
15:46:08 0.49 100 OTO
14:15:52 0.49 8500 OTO
13:50:29 0.49 1600 OTO
13:37:13 0.49 4000 OTO
13:33:42 0.49 700 OTO
13:31:32 0.49 2000 OTO
13:19:48 0.49 2395 OTO
12:12:02 0.49 1500 OTO
10:59:20 0.49 1000 OTO
10:13:08 0.49 10500 OTO
10:12:30 0.49 2000 OTO
10:06:54 0.49 1000 OTO
09:55:12 0.48 10000 OTO
and the .49's are GONE !!!
load the boat now before its to late,looks like the .49s will be gone soon...
time to load up before the next run towards the .04s
CRYO is starting the work through the .49s
hoping for some news this coming monday
bid .45 by ask .48.. it keeps moving up slowly!!
and (IMO) there will be more GREAT news moving forward in the near future again, .. this will be fun watching shorts chase the stock...lol
(IMO) shorts will be chasing it in the near future...
just posted on mcig fb page https://www.facebook.com/mCigInc/?hc_ref=NEWSFEED&fref=nf
bid .43 by .48 ...
the deal wasn't started, negotiated or completed in 2016... it was all done in 2017..
from MCIG FB Two containers full of equipment being moved into Solaris as we speak. Also, some additional updates to some of our other projects: http://mciggroup.com/project-updates/
https://www.facebook.com/mCigInc/?hc_ref=NEWSFEED&fref=nf
looks like the bid is starting to creep up... .41 by .48
MM's probably shaking out the weak hands before lift off...
MCIG pics and video on their fb page https://www.facebook.com/mCigInc/?hc_ref=NEWSFEED
LMAO at ALL the shorts.... MCIG upward and going STRONG...
good call md420
MCIG should be back up in the mid .20s in the near future.
something is DEFIANTLY up, 1 million on the bid at .033 just before close...
Do we have lift off here?
NEW MCIG deck out on social media... new company and time to load the boat !!
All aboard the train, train is about to leave the station !!
Bid and spread are starting to tighten !!
All that is needed is updated financials and some IR and PR to get the word out about the app, the company and Stock
NEWS out on CRYO ---EATONTOWN, NJ / ACCESSWIRE / May 23, 2017 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released summary corporate and financial highlight information regarding the Company's six months ending March 31, 2017 versus the same six month period in fiscal 2016:
- The Company's Total Revenue increased from $279,554 to $750,140, for the six month period for Fiscal 2017 versus Fiscal 2016
- Accounts Receivable increased 105% to $134,171 for the six month period for Fiscal 2017 versus Fiscal 2016
- Tissue storage and processing increased 168% in the six month period for 2017 versus the same period for Fiscal 2016
- Cost of revenue increased to $273,221 from $148,421 attributable to higher processing volumes but decreased as a percentage of revenue for the six month period from 53% in 2016 to 36% in 2017
- Professional fees increased (principally legal and accounting) to $44,104 in the six month period as compared to $30,623 for the same period in Fiscal 2016 due to an increase in legal expenses for the prosecution of our international patent portfolio, and optimization and scale up work associated with preparation of a number of pending 510k filings for our media, cryostorage and transportation products.
"American CryoStem's six months results for the period ended March 31, 2017 reflect the expansion of distribution of our products and services. During the balance of our Fiscal 2017, we will be seeking 510k registration of our products so that they are more readily accepted for use in the international markets," stated Anthony Dudzinski, COO.
John S. Arnone, CEO stated, "We have seen a steady increase of new patients utilizing our ATGRAFT tissue storage platform and individuals storing their stem cells for future use during the quarter. We are in discussions for new global territories with licensees seeking to establish our adipose tissue (fat) based collect-process-store, stem cell platform in their country. The increased interest in cellular therapies is evidenced in eight thousand (8,000+) plus clinical trials currently registered with ClinicalTrials.gov focused on adipose tissue and its derivatives, and a continued expansion of approved cellular therapies outside the US market." Arnone further stated, "We look forward to expanding our global laboratory consumable product sales as we open new territories and regenerative and personalized medicine applications become main stream."
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO); was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary, IRB approved, FDA compliant platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physicians networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For further detailed corporate or Regenerative Medicine information please visit:
www.americancryostem.com, request by email at info@americancryostem.com or phone 732-747-1007
SOURCE: American CryoStem Corporation
© Copyright © 2017 Accesswire. All rights reserved.
BOOM .037 !! lets go !!
MD-420 , i agree w/ you too..
agreed
peterbelt100
I'd say it should break it .035 soon
someone is trying to HOLD this stock down
I agree w/ you on LONG term of the news released
big run up and little selling.. this stock has a TOM of upside potential in my opinion !!
looks like its back to where it was trading a while back, im sure the mm's are waiting to see who will see the volume and sell.. (IMO) HOLD for the ride to come !!